EMA's regular press briefing on public health emergencies https://nitter.eu/i/broadcasts/1jMJgLMdkEYxL
We expect to see more #COVID19vaccines that are tailored to improve the immune response against emerging #COVID19 variants. #EMAPresser
Preliminary data show that adapted #COVID19vaccines increase the neutralisation of #Omicron subvariants compared to original COVID-19 vaccines. Revaccinations with the adapted vaccines increase protection against disease. #EMAPresser
We see no major increase in #COVID19 case rates in the EU due to high immunity in population following vaccination & natural infection. However, this could change rapidly as we are getting into winter months.
❗️The virus is keeping a fast pace in its evolution. #EMAPresser
📢Uptake of additional vaccine doses in last few months is rather disappointing: the European average is only 29% revaccinations in people most at risk.
❗️It is of concern that people at risk of hospitalisation or severe #COVID19 are not adequately protected. #EMAPresser
The risk of severe #COVID19 increases exponentially if you are 60 years or older.
❗️The older you are, the more you are at risk, and vaccines can save your life.
We encourage you to get vaccinated or re-vaccinated especially if you belong to higher risk groups. #EMAPresser
#COVID19: EMA is contributing to international activities to advance development of mucosal vaccines that are administered via the nose, mouth or inhalation, which could increase their ability to prevent infection and to block transmission. #EMAPresser
Heavy menstrual bleeding with mRNA #COVID19vaccines: our safety committee noted that most of cases appeared to be temporary & non-serious. There is no evidence showing the menstrual disorders experienced by some people have an impact on reproduction & fertility. #EMAPresser
EMA’s Emergency Task Force reviewed numerous studies which reaffirm that #COVID19vaccines are safe and provide protection for pregnant people & the babies they carry.
❗️Newborns are particularly vulnerable to the dire consequences of #COVID19 following infection. #EMAPresser
We are in contact with developers to advance next generation monoclonal antibodies against #COVID19 based on innovative clinical study design. We will discuss this with @US_FDA and international experts in December 2022. #EMAPresser
Outbreak of #Ebola Sudan virus in Uganda: We are supporting the @WHO for rapid implementation of #clinicaltrials to establish the efficacy and safety of therapeutics and vaccines. #EMAPresser
There are high concerns that new emerging #Omicron subvariants are escaping neutralisation by available monoclonal antibody medicines against #COVID19. We will review all available data to issue new recommendations to healthcare professionals. #EMAPresser
🐦🔗: https://nitter.eu/EMA_News/status/1595766679035854849